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Abstract: Costs of drugs used for the treatment for 1 year were compared before and
after spa therapy in 16 patients with asthma in relation to disease severity. Asthma
severity was classified as : stage 1 (intermittent), 2 (mild persistent), 3 (moderate
persistent), and 4 (severe persistent). 1. The total cost of drugs used for each pa-
tient for 1 year clearly decreased in all groups. The %decrease of the costs of drugs
in each group was 27.2% in patients with stage 1, 43.5% in those with stage 2 and
34.1% in those with stage 3-4 (mean 34.5%). The reduction of the cost of
bronchodilators was predominant in patients with stage 3- 4, and the decrease in the
cost of corticosteroids predominant in those with stage 2. The reduction of costs of
antiallertgics, mucolytics, and antibiotics was predominant in patients with stage 2 and
stage 3- 4. The %reduction in the cost of corticostroids was remarkable in patients
with stage 2. The %decrease in the costs of mucolytics and antibiotics was predomi-
nant in patients with stage 2 and stage 3- 4. The results obtained here suggest that
the costs of drugs used for astmatics could be reduced by long-term spa therapy,
and the reduction of the costs was larger as asthma stage became more severe.
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Introduction
Asthma is clinically characterized by transient
wheezing and dyspnea, which are elicited by
bronchospasm , mucus hypersecretion 1 ) and
edema of mucous membrane. Our previous
studies have shown that spa therapy is effective
for patients with asthma, in which improvement
of subjective and objective symptoms 2 . 3), and
pulmonary function 4 • 5), suppression of bronchial
hyperresponsiveness 6 ), and improvement of sup-
pressed function of adrenocortical glands 7) •
Regarding the onset mechanisms of asthma,
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IgE-mediated allergy plays an important role, in
which an increase in the generation of leukotriene
C4 (LTC4) related to bronchospasm S -lO), and
leukotriene B4 (LTB4) related to bronchial
hyperresponsivenessll -13), is observed. The leu-
kocytes of the asthmatics generated significantly
more LTB4 and LTC4 than those of healthy
controls. In addition, it has been reported that
there is a significant correlation between LTB4
generation by leukocytes and the degree of
bronchial hyperresponsiveness to methacholine 13) •
Asthma has been treated mainly with
antiasthmatic drugs such asbronchodilators,
glucocrticoids , antiallergic agents, mucolytics
and antibiotics.
The process of development of drugs for the
treatment of asthma has shown that asthma
symptoms could be improved more easily with
newly developed drugs such as inhaled
corticosteroids and bronchodilators. However,
the costs of drugs of them are relativery high,
and the number of patients with asthma has
been increasing in recent years. Thus, sev-
eral pharmacoeconomic studies in asthma have
been conducted in the USN'-16) and Europe 17-ZO).
In the present study, the effects of spa ther-
apy on reduction of costs of drugs used for the
treatment of asthma was studied in relation to
disease severity.
Subjects and Methods
drugs used for the treatment of asthma per pa-
tient were compared between the cost of drugs
for 1 year from January to December in 1997
when spa therapy started and that from January
to December in 2000 after spa therapy begun.
Spa therapy, particularly, swimming training in
a hot spring pool, was continued. The total
costs of all drugs and the cost of each drug
were expressed throughout in ¥.
Asthma severity was evaluated according to
international guidelinesZ!). Assessments of sever-
ity were classified as: 1) intermittent; 2)
mild persistent; 3) moderate persistent; 4)
severe persistent. In this study, the costs of
drugs used per patient for 1 year were com-
pared among three stages ; stage 1, stage 2 and
stage 3-4.
Statistically significant differences of the mean
were estimated using the unpaired Student't test.
A p value of <0.05 was regarded as significant.
Results
The costs of drugs used for treatment per pa-
tient with asthma for 1 year decreased in all
groups classified by asthma stage after spa ther-
apy for 3 years, compared with the costs for 1
year when the therapy started (Table 1 ). The
% decrease in the costs of total drugs used was
the largest in patients with stage 2.
Table 1. Costs of drugs used for treatment per patient for 1 year
before and after spa therapy
Data are presented as¥
The mean decrease in the costs of drugs in
all groups was 34.5% (Fig. 1). The reduction of
the mean cost of bronchodilators after spa therapy
Asthma stage5pa _
therapy 3-4
The subjects of this study were 16 patients (9
females and 7 males) with asthma. The age of
all patients was over 65 years with a mean age
of 71. 4 years (range 65-78 years). All patients
were treated with antiasthmatic drugs such as
bronchodilators, corticosteroids, antiallergics,
mucolytics, antibiotics, and others (physiologi-
cal saline, drugs for common cold, etc) at
Misasa Medical Center for 1 year. The costs of
Drugs
Total
Before
After
103,350
75,250
158,990
_89,840
385,900
254,370
47 Reduction of the costs of the drugs by spa therapy in asthma
Stage 1 Stage 2 Stage 3-4
Asthma stage
Fig.1. The % reduction of the cost of total drugs after spa
therapy compared with the costs before the therapy.
was largest from ¥108,090 to ¥66,140 in
patients with stage 3-4 ; the difference before
and after spa therapy was ¥ 41, 950 per patient for
1 year (Fig. 2 a). However, the % reduction of
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Fig.3a. Comparison between the costs of corticosteroids
before (B) and after (A) spa therapy in patients with
asthma
The reduction of the cost of corticosteroids
was the largest from ¥ 19, 200 to ¥ 7930 (diffe-
rence : ¥ 11, 270)in patients with stage 2 (Fig. 3 a).
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Fig.3b. The % reduction of the cost of corticosteroids after
spa therapy compared with the costs before the
therapy.
Furthermore, the % decrease in the cost of
corticosteroids was also the largest (58.7%) in
patients with stage 2 (Fig. 3 b). The cost of
antiallergics was also reduced after spa therapy.
The decrease of the cost of antiallergics was
predominant in patients with stage 2 (differ-
ence ¥ 33,450) and group 3-4 (¥ 48,910) as
shown in Fig. 4 a. The %decrease in the cost
of antiallergics was the largest in patients with
stage 2 (37.3%) and the smallest in those with
stage 3-4 (25.7%) (Fig. 4 b).
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Fig. 2a. Comparison between the costs of bronchodilators
before (B) and after (A) spa therapy in patients with
asthma
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Stage 1
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Asthma
stage
the cost of drugs was almost similar between
32.8% and 40.0% in all groups (Fig. 2 b) .
Fig.2b. The % reduction of the cost of bronchodilators after
spa therapy compared with the costs before the
therapy.
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(¥)
200,000
%) and stage 3-4 (48.6%) (Fig. 5 b).
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Fig.5b. The % reduction of the cost of mucolytics after spa
therapy compared with the costs before the therapy.
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Fig.Ga. Comparison between the costs of antibiotics before
(8) and after (A) spa therapy in patients with asthma.
a and b:p<0.05.
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the cost of antibiotics was also predominant in
patients with stage 2 (93.6%) and stage 3-4
(86.4%) (Fig. 6 b).
The cost of antibiotics significantly decreased
in patients with stage 2 (from ¥ 4,220 to 270)
(p<0.05) and stage 3-4 (from ¥ 15,110 to
2,060) (p< 0.05) (Fig. 6 a). The %decrease in
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Fig.5a. Comparison between the costs of mucolytics before
(8) and after (A) spa therapy in patients with asthma
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Fig.4b. The % reduction of the cost of antiallergics after
spa therapy compared with the costs before the
therapy.
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The cost of mucolytics clearly decreased in
patients with stage 2 (difference ¥11,900) and
stage 3-4 (¥ 13, 700) after spa therapy for 3 years.
However, the decrease of mucolytics in patients
with stage 1 was not predominant (Fig. 5 a).
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The % decrease in the drug of mucolytics was
also predominant in patients with stage 1(60. 0
Fig.6b. The % reduction of the cost of antibiotics after spa
therapy compared with the costs before the therapy.
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Discussion
In recent years, the number of patients with
asthma, particularly elderly asthmatics, has been
increasing. Furthermore, many antiasthmatic
drugs such as inhaled sympathomimetics, in-
haled corticosteroids and leukotriene C4 recep-
tor antagonists have been developed. Due to
the newly developed drugs, the treatment of
asthma has become more easily, and more pa-
tients with asthma has become to be controlla-
ble by drugs. However, the costs of these
newly developed drugs are in general considera-
bly high. Particularly, the use of prescribed in-
haled sympathomimetics and corticosteroids has
been increasing with severity of illness14,15). In
addition, the number of patients with asthma,
particularly, of elderly asthmatics, has been in-
creasing in recent years in Japan.
Our previous studies have shown that spa
therapy is effective in patients with asthma by
improving subjective and objective symptoms2,3),
pulmonary function 4 , 5,22-24), an increased bron-
chial hyperresponsiveness6), and suppressed
function of adrenocortical glands 7). In the pre-
sent study, the effects of spa therapy on reduc-
tion of the costs of drugs used for the treatment
for asthma were examined.
Regarding the costs of medication for asthma
treatment, several reports suggest a close corre-
lation between the costs of medication and dis-
ease severity in asthma. The most empirical
data, for 1995-1996, clearly showed an in-
creased costs depending upon illness severityI6).
Other reports have also demonstrated an enor-
mous increase as total costs' as asthma severity
increases 14-20). It has been also reported that
pharmacotherapy for asthma is underused or in
adequate. In particular, treatment with inhaled
corticosteroids is insufficient. In contrast, short-
term sympathomimetics are exessively prescribed.
Only one-third of asthma patients were treated
according to asthma guidelines14) •
In this study, the reduction of the costs of drugs
used for the treatment of asthma by spa therapy
was examined in 16 patients with asthma. The re-
sults obtained here demonstrated that the total
costs of drugs for asthma such as bronchodilators,
corticosteroids, antiallergics, mucolytics, and
antibiotics clearly decreased after spa therapy
for 3 years. The mean %decrease in the costs
of all drugs was 34.5%. Regarding the reduc-
tion of the costs of drugs, the reduction in the
cost of bronchodilators was found to be remark-
able in patients with stage 3-4. The decrease in
the costs of corticosteroids was remarkable in
patients with stage 2. The reduction of the
costs of antiallergics, mucolytics, and antibiotics
was remarkedly observed in patients with stage
2 and stage 3-4.
In contrast, regarding the %decrease in the
costs of drugs, the decrease ratio showed al-
most same tendency as the reduction of the
costs of drugs. However, the %decrease in the
costs of bronchodilators was not different among
three groups, and futhermore, the %decrease
in the costs of antiallergics was predominant in
patients with stage 1 and stage 2. The results
demonstrated that the reduction of the costs of
drugs could be attained by spa therapy and that
the reduction after spa therapy was larger as
asthma severity became more severe.
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温泉療法による気管支嘱息に対する年間薬剤費の
削減
芦田耕三,光延文裕,保崎泰弘,清田全紀 1),
岩垣尚史,藤井 誠,高田真吾,谷崎勝朗
岡山大学医学部 ･歯学部附属病院三朝医療センター
内科, 1)リハビリテーション科
気管支職息16例を対象に,治療のために要した
年間薬剤費が温泉療法により削減可能であるのか
どうかについて,国際ガイドラインの重症度分類
(stageト4)別に若干の検討を加えた｡1.年間
の総薬剤費は重症度別の全てのグループにおいて
明らかに減少した.2.その削減率は,ステージ
1で27.2%,ステージ2で43.5%,ステージ3-
4で34.1%であり,その平均は34.5%であった｡
3.気管支拡張剤の薬剤費の減少はステージ3-
4で高度であり,副腎皮質ホルモンの薬剤費の減
少はステージ2で著明であった｡また,抗アレル
ギー薬,去痩薬,抗生物質などの薬剤費の削減は,
ステージ2および3-4で高度であった｡4.削
減率では,去壊薬,抗生物質の削減率が,2およ
び3-4で著明であった｡
以上の結果より,温泉療法により,気管支嘱息
の治療に必要な薬剤費は削減可能であること,そ
して,温泉療法による薬剤費の削減は職息の重症
度が高い症例でより高度であることが示唆された｡
